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In a recent Science paper, Teles et al. (2013) show that type I and II interferons (IFNs) are reciprocally
expressed in the polar immune forms of leprosy, with type I IFNs inducing IL-10 that interferes with the
antimycobacterial effects of type II IFNs (IFNg) at the site of infection.Leprosy, caused by the bacterium
Mycobacterium leprae, has a long tradi-
tion as a stigmatized disease, but also
serves as the paradigmatic human infec-
tion that evokes polarized cellular immune
responses. The two polar forms of
leprosy, termed tuberculoid and leproma-
tous, have clinical, microbiological, and
immunological distinctions. Tuberculoid
leprosy is characterized by few skin le-
sions, low numbers of bacteria in lesions,
and histologically well-formed granu-
lomas containing abundant CD4 T cells,
while lepromatous leprosy is character-
ized by numerous infiltrative skin lesions,
large numbers of bacteria in lesions, and
poorly formed granulomas with fewer
lymphocytes. Since the seminal discovery
that identified a predominance of Th1
CD4 T cells in lesions of tuberculoid
leprosy and Th2 cells in lepromatous
lesions (Salgame et al., 1991), which
activate the cellular and humoral immune
responses, respectively, further investiga-
tion has yielded evidence that the proin-
flammatory cytokine IL-12 (Sieling et al.,
1994) and multiple other cytokines are
differentially expressed at the site of dis-
ease in the polar forms of leprosy.
In a recent paper in Science, Teles et al.
present evidence that the anti-inflamma-
tory cytokine IL-10 induced by type I
interferons (IFNs) is a factor promoting
lepromatous leprosy (Teles et al., 2013)
(Figure 1). The authors first characterizedthe transcriptional signatures of skin le-
sions from both forms of leprosy. To
separate the broadly overlapping type I
and type II IFN-induced signatures that
they detected, they took advantage of
publicly available gene data sets specific
for responses to each type of IFN. They
revealed an overrepresentation of type I
IFN (IFNa/b)-induced genes, particularly
IL-10, in lepromatous lesions, whereas
tuberculoid lesions are significantly en-
riched in transcripts induced by type II
IFN (IFNg), including those of the
antimycobacterial vitamin D pathway.
Teles et al. also showed that the transcrip-
tional profile of reversal reaction (RR) le-
sions, which characterize a transition
from the lepromatous toward the tubercu-
loid end of the spectrum, clusters with
that of the latter. Interestingly, type I and
type II IFN-driven signatures seemed to
be mutually exclusive in each polar form
of the disease. Beyond leprosy, the au-
thors compared their results to recently
published studies of blood transcriptional
signatures in patients with active tuber-
culosis (Teles et al., 2013; Berry et al.,
2010; Maertzdorf et al., 2012) and pro-
posed a common type I IFN-inducible
gene program that correlates with
severity of mycobacterial infections. The
authors then strengthened their case by
measuring the increased levels of Ifnb,
one of the 14 type I IFNs, and Ifnar1, the
specific receptor for type I IFNs, tran-scripts, and proteins in lepromatous
versus tuberculoid or RR lesions. They
found a positive correlation between
type I IFNs and IL-10 mRNA levels and
colocalization of the corresponding pro-
teins in lepromatous lesions. To decipher
the functional correlation between these
cytokines, they showed in vitro that hu-
man blood monocytes produce type I
IFNs and IL-10 in response to live or son-
icated M. leprae and that the production
of IL-10 is at least partially dependent
on type I IFNs signaling through their
specific receptor. Finally, following a se-
ries of microarray analyses of skin lesions
and in vitro experiments, the authors
concluded that type I IFN-induced pro-
duction of IL-10 in lepromatous lesions
inhibits type II IFN-induced genes and
networks, such as antimicrobial peptides
or the vitamin D pathway, with a direct
consequence on the ability of mono-
cytes/macrophages to control the intra-
cellular growth of M. leprae.
The reciprocal changes in cytokine
expression in tuberculoid and leproma-
tous leprosy have revealed evidence for
complex cytokine regulatory networks at
the site of infection in a human disease,
yet they leave open an important ques-
tion: What is the initial determinant of the
polar immune responses to M. leprae?
Bacterial diversity is unlikely, given the
extremely high relatedness of leprosy
bacilli genomes worldwide (Monot et al.,13, April 17, 2013 ª2013 Elsevier Inc. 377
Figure 1. The Role of Interferons in the Spectrum of Leprosy
High bacterial loads; numerous lipid-rich, myeloid-derived foam cells; and rare lymphocytes characterize
lepromatous leprosy. Those lesions are associated with a type I IFN- or IFNa/b-driven transcriptional
signature, including the production of IL-10. IL-10 inhibits downstream antimycobacterial effectors
induced by type II interferon, or IFNg, which are the hallmark of the better-controlled form, tuberculoid
leprosy, and of reversal reaction (RR) lesions, a transitional form of the disease. In tuberculoid leprosy le-
sions, only a few bacteria can be found inmacrophages, surrounded by numerous CD4+ T cells, organized
in well-formed granulomas.
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as the likely mechanism. Recent studies
of human genetic susceptibility have re-
vealed evidence for leprosy susceptibility
determined by loci that include genes en-
coding NOD2 and RIP2K involved in
intracellular bacterial recognition and
signaling as well as the receptor for the in-
flammatory cytokine IL-23 (IL23R), along
with other loci shared with susceptibility
to Crohn’s disease, another disease char-
acterized by granulomatous inflammation378 Cell Host & Microbe 13, April 17, 2013 ªand a link to microbial exposure (Zhang
et al., 2009). However, those studies
compared subjects with leprosy to con-
trols without leprosy, so it is unclear
whether those loci also influence the po-
larity of T cell responses and the clinical
and immunological form of the disease.
Therefore, additional concerted efforts
are needed to identify the initial determi-
nants and responses that determine the
ultimate immunological, microbiological,
and clinical outcomes of M. leprae infec-2013 Elsevier Inc.tion. These efforts will surely yield impor-
tant information of great scientific interest,
and these may have significance for vac-
cine and adjuvant design.REFERENCES
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